STOCK TITAN

Intellia Therapeutics Inc - NTLA STOCK NEWS

Welcome to our dedicated news page for Intellia Therapeutics (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Intellia Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Intellia Therapeutics's position in the market.

Rhea-AI Summary
Intellia Therapeutics receives FDA clearance for NTLA-2001 gene editing therapy for ATTR amyloidosis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.75%
Tags
-
Rhea-AI Summary
Intellia Therapeutics Receives PRIME Designation for NTLA-2002 in the Treatment of Hereditary Angioedema
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.18%
Tags
none
-
Rhea-AI Summary
Regeneron and Intellia expand collaboration to develop CRISPR-based gene editing therapies for neurological and muscular diseases. Collaboration combines Intellia's genome editing platform with Regeneron's viral vector delivery technologies. Companies will initially research two non-liver targets. Each company has the opportunity to lead development and commercialization for one target.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
none
Rhea-AI Summary
Intellia Therapeutics reports operational highlights and financial results for Q2 2023. They have completed patient identification for Phase 2 study of NTLA-2002 for hereditary angioedema (HAE) and plan to initiate Phase 3 study in Q3 2024. They also plan to submit IND application for NTLA-2001 for ATTR amyloidosis and present additional clinical data in 2023. They expect to submit CTA for NTLA-3001 for alpha-1 antitrypsin deficiency (AATD)-associated lung disease. They ended Q2 2023 with $1.1 billion in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
-
Rhea-AI Summary
Intellia Therapeutics, Inc. (NASDAQ:NTLA) to present Q2 2023 financial results and operational highlights on August 3, 2023. Join the conference call for insights into the company's progress and future prospects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.69%
Tags
management
-
Rhea-AI Summary
Intellia Therapeutics reports operational highlights and financial results for Q1 2023, including the dosing of the first patient in the Phase 2 study of NTLA-2002 for hereditary angioedema and plans to submit an IND application for NTLA-2001 for ATTR amyloidosis. The company ended the quarter with approximately $1.2 billion in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.14%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
Intellia Therapeutics Inc

Nasdaq:NTLA

NTLA Rankings

NTLA Stock Data

2.33B
94.53M
1.33%
87.42%
15.43%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About NTLA

intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the